Document Detail


In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time.
MedLine Citation:
PMID:  19055570     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Low-molecular-weight heparin (LMWH) is being used increasingly in veterinary medicine for both treatment and prophylaxis of thromboembolic disease, but no predictable patient-side method exists to monitor its effect. OBJECTIVES: The aim of this study was to evaluate thromboelastography (TEG) and prothombinase-induced clotting time (PiCT) assays for detecting hemostatic alterations following in vitro heparinization of canine whole blood with dalteparin (Fragmin). METHODS: Citrated whole-blood samples were collected from 7 clinically healthy dogs. Dalteparin was added at concentrations of 0, 0.156, 0.625, 1.25, and 2.5 U/mL of whole blood. TEG was performed using heparinase cups with tissue factor (TF, 1:50,000) and kaolin as activators. Reaction time (R), clotting time (K), angle (alpha), and maximum amplitude (MA) were recorded. PiCT and anti-FXa activity were measured in plasma. RESULTS: With TF, increasing concentrations of dalteparin significantly prolonged R and K and significantly decreased alpha and MA. K, alpha, and MA ratios were significantly different from baseline at all dalteparin concentrations and R was significantly different from baseline at concentrations of 0.625, 1.25, and 2.5 U/mL. With kaolin, only R was significantly different from baseline at dalteparin concentrations of 0.625 and 2.5 U/mL. PiCT detected dalteparin concentrations < or = 0.625 U/mL, with a good linear correlation (r(2)=.96, P<.0001). CONCLUSION: These results suggest that TF-activated TEG and PiCT assays should be further evaluated as promising new methods for evaluating the effect of LMWH, using doses in the recommended clinical range and prospective clinical studies.
Authors:
Lisbeth R Jessen; Bo Wiinberg; Asger L Jensen; Mads Kjelgaard-Hansen; Kate H Jensen; Lotte B Pedersen; Annemarie T Kristensen
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Veterinary clinical pathology / American Society for Veterinary Clinical Pathology     Volume:  37     ISSN:  0275-6382     ISO Abbreviation:  Vet Clin Pathol     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-05     Completed Date:  2009-01-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9880575     Medline TA:  Vet Clin Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  363-72     Citation Subset:  IM    
Affiliation:
Department of Small Animal Clinical Sciences, Faculty of Life Sciences, University of Copenhagen, Denmark. lrmj@life.ku.dk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticoagulants / pharmacology
Blood Coagulation / drug effects
Dalteparin / pharmacology*
Dogs
Dose-Response Relationship, Drug
Female
Heparin Lyase / metabolism*
Kaolin
Male
Thrombelastography / veterinary*
Thromboplastin / metabolism*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Dalteparin; 1332-58-7/Kaolin; 9035-58-9/Thromboplastin; EC 4.2.2.7/Heparin Lyase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Age-Related Pregnancy Results and Further Examination of Bitches after Aglepristone Treatment of Pyo...
Next Document:  Comparative clinical study of canine and feline total blood cell count results with seven in-clinic ...